Demonstrates improved survival and lower high-grade toxicity with pembrolizumab over ipilimumab in advanced melanoma, highlighting its therapeutic benefit.
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
No takes yet. Share an insight, caveat, or question.
Robert et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: